Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman

Annals of Pharmacotherapy

Volumn 38, Issue 10, 2004, Pages 1643-1647

  Mallet, Louise ^a,b   Babin, Steve ^c   Morais, José A ^b,d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c Pharmacy Uniprix   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Hyperammonemia; Thrombocytopenia; Valproic acid

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; CARBAMATE KINASE; GABAPENTIN; LOSARTAN; PANTOPRAZOLE; VALPROATE SEMISODIUM; VALPROIC ACID;

AGED; AMINO ACID METABOLISM; AMMONIA FORMATION; ARTICLE; CASE REPORT; COGNITION; CONCENTRATION RESPONSE; CONFUSION; DOSE RESPONSE; ELDERLY CARE; ELECTROENCEPHALOGRAM; EMERGENCY WARD; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITALIZATION; HUMAN; HYPERAMMONEMIA; MENTAL HEALTH; MITOCHONDRIAL MEMBRANE; MUSCLE WEAKNESS; NAUSEA; PATIENT MOBILITY; PRIORITY JOURNAL; PROBABILITY; SEIZURE; SOMNOLENCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UREA CYCLE; VOMITING;

AGED; AMMONIA; ANTICONVULSANTS; FEMALE; HUMANS; HYPERAMMONEMIA; PLATELET COUNT; THROMBOCYTOPENIA; VALPROIC ACID;

EID: 4644320399     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E063     Document Type: Article

References (29)

1. Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drag Rev 2003;9:199-216.
2. Feil D, Chuang K, Sultzer DL. Valproate-induced hyperammonemia as a cause of altered mental status. Am J Geriatr Psychiatry 2002;10:476-8.
3. Zaret BS, Beckner RR, Marini AM, Wagle W, Passarelli C. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology 1982;32:206-8.
4. Panikkar GP, Gilman SM. Valproate-induced hyperammonemia in the psychiatric setting: 2 cases. J Clin Psychiatry 1999;60:557-9.
5. Duarte J, Macias S, Coria F, Fernandez E, Claveria LE. Valproate-induced coma: case report and literature review. Ann Pharmacother 1993; 27:582-3.
6. Rawat S, Borkowski WJ, Swick HM. Valproic acid and secondary hyperammonemia. Neurology 1981;31:1173-4.
7. Jones GL, Matsuo F, Baringer JR, Reichert WH. Valproic acid-associated encephalopathy. West J Med 1990;153:199-202.
8. Gaskins JD, Holt RJ, Postelnick M. Nondosage-dependent valproic acid-induced hyperammonemia and coma. Clin Pharm 1984;3:313-6.
9. Trannel TJ, Ahmed I, Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry 2001;158:128-30.
10. Cockcroft DW, Gault WH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
11. Folstein MF, Folstein SE, McHugh PR. Mini-Mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
12. Heimberger T. 2002. Depakote/Depakene/Depacon (divalproex sodium/valproic acid/valproate sodium). Important drug warning. Abbott Pharmaceutical Division. 2002 Safety alerts for drugs, biologies, medical devices, and dietary supplements. Food and Drug Administration, www.fda.gov/medwatch/SAFETY/2002/ depakote_deardoc.pdf (accessed 2004 Apr 5).
13. Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 2002;17:367-73.
14. Martin G, Durozard D, Besson J, Baverel G. Effect of the antiepileptic drug sodium valproate on glutamine and glutamate metabolism in isolated human kidney tubules. Biochim Biophys Acta 1990;1033:261-6.
15. Rumbach L, Cremel G, Marescaux C, Warter JM, Waksman A. Valproate-induced hyperammonemia of renal origin. Biochem Pharmacol 1989;38:3963-7.
16. Marini AM, Zaret BS, Beckner RR. Hepatic and renal contributions to valproic acid-induced hyperammonemia. Neurology 1988;38:365-71.
17. Raby WN. Carnitine for valproic acid-induced hyperammonemia. Am J Psychiatry 1997;154:1168-9.
18. Hamer HM, Knake S, Schomburg U, Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000;54:230-2.
19. Laub MC, Paetzke-Brunner I, Jaeger G. Serum carnitine during valproic acid therapy. Epilepsia 1986;27:559-62.
20. Bohles H, Sewell AC, Wenzel D. The effect of carnitine supplementation in valproate-induced hyperammonaemia. Acta Paediatr 1996;85: 446-9.
21. Murakami K, Sugimoto T, Woo M, Nishida N, Muro H. Effect of 1-carnitine supplementation on acute valproate intoxication. Epilepsia 1996; 37:687-9.
22. Zelnik N, Fridkis I, Gruener N. Reduced carnitine and antiepileptic drugs: cause relationship or co-existence? Acta Paediatr 1995;84:93-5.
23. Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982;101:782-5.
24. Oluboka OJ, Haslam D, Gardner DM. Pancytopenia and valproic acid: a dose-related association. J Am Geriatr Soc 2000;48:349-50.
25. Eastham RD, Jancar J. Sodium valproate and platelet counts (letter). Br Med J 1980;280:186.
26. May RB, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia 1993;34:1098-101.
27. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
28. Oeschsner M, Steen C, Sturenburg HJ, Kohlschutter A. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. Neurol Neurosurg Psychiatry 1998;64:680-2.
29. Incalzi RA, Landi F, Cipriani L, Bruno E, Pagano F, Gemma A, et al. Nutritional assessment: a primary component of multidimensional geriatric assessment in the acute care setting. J Am Geriatr Soc 1996;44:166-74.